India, June 16 -- Tuesday's top gainers include CervoMed, with key clinical trial catalysts ahead; Conexeu, which strengthened its leadership with board expansion; NeOnc, advancing its lead drug candidate into Phase 2 for aggressive brain tumours; and Simulations Plus, which is set to be acquired by Altaris affiliates, among others.
Read on...
CRVO Poised for a Transformative 2026
CervoMed Inc. (CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, soared more than 80% on Tuesday on no specific news.
The company's lead drug candidate is Neflamapimod, which is currently in clinical development for the treatment of dementia with Lewy bodies (DLB), recovery after ischemic stroke, and primary p...